Brief: Theranexus, Inserm Transfert Partner In Rare Neurological Diseases
20/10/2022 17:11
Oct 20 (Reuters) - THERANEXUS SA ALTHX.PA :
* THERANEXUS AND INSERM TRANSFERT SIGN A STRATEGIC ALLIANCE
TO
IDENTIFY DRUG CANDIDATES FOR INNOVATIVE THERAPIES IN RARE
NEUROLOGICAL DISEASES
Source text for Eikon: ID:nACT76822
Further company coverage: ALTHX.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))
Recent news on Thx Pharma SA
See all newsBrief: Theranexus And BBDF Announce Final And Positive Safety And Efficacy Data In The Phase I/II Trial Testing Batten-1
Brief: Theranexus End-Dec Total Available Funds Stood At EUR 4.9 Mln
Brief: Theranexus Declares Encouraging Prelim Results For Batten Disease Drug
Brief: Theranexus And BBDF Granted Positive Opinion By EMA For Design Of Batten-1 Phase III Trial
Brief: Theranexus And BBDF Win FDA Approval On Endpoints For Phase III Trial To Evaluate Batten-1 In CLN3 Batten Disease